Advanced search
Publication Cover
Expert Opinion on Drug Metabolism & Toxicology Volume 5, 2009 - Issue 6
Submit an article Journal homepage
603
Views
44
CrossRef citations to date
0
Altmetric
Drug Evaluations

Rifaximin pharmacology and clinical implications

Veronica Ojetti Catholic University of Sacred Heart, Gemelli Hospital, Internal Medicine Department, Largo A. Gemelli, 8; 00168 Rome, Italy +39 06 3015 6018; +39 06 3550 2775; veronica.ojettitin.it
,
Ernesto Cristiano Lauritano Catholic University of Sacred Heart, Gemelli Hospital, Internal Medicine Department, Largo A. Gemelli, 8; 00168 Rome, Italy +39 06 3015 6018; +39 06 3550 2775; veronica.ojettitin.it
,
Federico Barbaro Catholic University of Sacred Heart, Gemelli Hospital, Internal Medicine Department, Largo A. Gemelli, 8; 00168 Rome, Italy +39 06 3015 6018; +39 06 3550 2775; veronica.ojettitin.it
,
Alessio Migneco Catholic University of Sacred Heart, Gemelli Hospital, Internal Medicine Department, Largo A. Gemelli, 8; 00168 Rome, Italy +39 06 3015 6018; +39 06 3550 2775; veronica.ojettitin.it
,
Maria Elena Ainora Catholic University of Sacred Heart, Gemelli Hospital, Internal Medicine Department, Largo A. Gemelli, 8; 00168 Rome, Italy +39 06 3015 6018; +39 06 3550 2775; veronica.ojettitin.it
,
Luigi Fontana Washington University School of Medicine, Division of Geriatrics & Nutritional Sciences, St Louis, USA
,
Maurizio Gabrielli Catholic University of Sacred Heart, Gemelli Hospital, Internal Medicine Department, Largo A. Gemelli, 8; 00168 Rome, Italy +39 06 3015 6018; +39 06 3550 2775; veronica.ojettitin.it
&
Antonio Gasbarrini Catholic University of Sacred Heart, Gemelli Hospital, Internal Medicine Department, Largo A. Gemelli, 8; 00168 Rome, Italy +39 06 3015 6018; +39 06 3550 2775; veronica.ojettitin.it
 show all
Pages 675-682 | Published online: 15 May 2009

Citations (44)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Yuanzhen Liu, Xiqing Cui, Zhengyuan Li, Xu Chen, Guoping Zeng & Yuhui Sun. (2021) Production of 3-desmethyl protostreptovaricin I from the genetically engineered Streptomyces spectabilis CCTCC M2017417. Journal of Asian Natural Products Research 23:10, pages 1015-1021.
Read now
Eugenia Bruzzese, Marcella Pesce, Giovanni Sarnelli & Alfredo Guarino. (2018) Pharmacokinetic drug evaluation of rifaximin for treatment of diarrhea-predominant irritable bowel syndrome. Expert Opinion on Drug Metabolism & Toxicology 14:7, pages 753-760.
Read now
Lucrezia Laterza, Gianluca Ianiro, Iolanda Scoleri, Rosario Landi, Giovanni Bruno, Franco Scaldaferri, Eleonora Gaetani, Mariachiara Campanale & Antonio Gasbarrini. (2015) Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome. Expert Opinion on Pharmacotherapy 16:4, pages 607-615.
Read now
J Henrion & P Deltenre. (2013) DECOMPENSATED CIRRHOSIS … ARE WE GAINING GROUND?. Acta Clinica Belgica 68:6, pages 411-415.
Read now
Giovanni Latella & Carmelo Scarpignato. (2009) Rifaximin in the management of colonic diverticular disease. Expert Review of Gastroenterology & Hepatology 3:6, pages 585-598.
Read now

Articles from other publishers (39)

Chenchen Meng, Xiaoming Wang, Lu Fan, Yajie Fan, Zhipeng Yan, Yunjiao Wang, Yanyang Li, Junping Zhang & Shichao Lv. (2024) A new perspective in the prevention and treatment of antitumor therapy-related cardiotoxicity: Intestinal microecology. Biomedicine & Pharmacotherapy 170, pages 115588.
Crossref
Mei Luo, Peiwei Xie, Xuehong Deng, Jiahui Fan & Lishou Xiong. (2023) Rifaximin Ameliorates Loperamide-Induced Constipation in Rats through the Regulation of Gut Microbiota and Serum Metabolites. Nutrients 15:21, pages 4502.
Crossref
Pushkala K & Gupta Purshottam D. (2023) Faecal Transplant Therapy: A Promising Treatment Modality for Cardiovascular Diseases. Journal of Cardiology and Cardiovascular Medicine 8:2, pages 108-113.
Crossref
Maurizio Koch, Alberto Enrico Maraolo, Giuseppe Natoli & Salvatore Corrao. (2023) Preventing acute diverticulitis. any roles for non-absorbable antibiotics? in search of evidence: a systematic review, meta-analysis, and trial sequential analysis. Frontiers in Gastroenterology 2.
Crossref
Won Moon, Sangwook Lim, Yeonsoon Jung, Yuk Moon Heo, Seun Ja Park, Moo In Park, Sung Eun Kim, Jae Hyun Kim & Kyoungwon Jung. (2022) The effects of rebamipide, sucralfate, and rifaximin against inflammation and apoptosis in radiation-induced murine intestinal injury. Kosin Medical Journal 37:4, pages 320-341.
Crossref
Mujtaba Aamir Bhat, Awdhesh Kumar Mishra, Javeed Ahmad Tantray, Hanan Ali Alatawi, Mohd Saeed, Safikur Rahman & Arif Tasleem Jan. (2022) Gut Microbiota and Cardiovascular System: An Intricate Balance of Health and the Diseased State. Life 12:12, pages 1986.
Crossref
Buyun Qian, Kaiyu Zhang, Yuan Li & Kangyun Sun. (2022) Update on gut microbiota in cardiovascular diseases. Frontiers in Cellular and Infection Microbiology 12.
Crossref
Yahkub Babatunde Mutalub, Monsurat Abdulwahab, Alkali Mohammed, Aishat Mutalib Yahkub, Sameer Badri AL-Mhanna, Wardah Yusof, Suk Peng Tang, Aida Hanum Ghulam Rasool & Siti Safiah Mokhtar. (2022) Gut Microbiota Modulation as a Novel Therapeutic Strategy in Cardiometabolic Diseases. Foods 11:17, pages 2575.
Crossref
Darshan Mehta, Miao Li, Noriko Nakamura, Mani Chidambaram, Xiaobo He, Matthew S. Bryant, Ralph Patton, Kelly Davis & Jeffrey Fisher. (2022) In vivo pharmacokinetic analyses of placental transfer of three drugs of different physicochemical properties in pregnant rats. Reproductive Toxicology 111, pages 194-203.
Crossref
Nesreen Nabil Omar, Rasha A. Mosbah, Wedad S. Sarawi, Marwa Medhet Rashed & Amira M. Badr. (2022) Rifaximin Protects against Malathion-Induced Rat Testicular Toxicity: A Possible Clue on Modulating Gut Microbiome and Inhibition of Oxidative Stress by Mitophagy. Molecules 27:13, pages 4069.
Crossref
Carmelo Scarpignato & Neil Stollman. 2022. Colonic Diverticular Disease. Colonic Diverticular Disease 209 234 .
Tingting Yan, Yuhong Luo, Yangliu Xia, Keisuke Hamada, Qiong Wang, Nana Yan, Kristopher W. Krausz, Jerrold M. Ward, Haiping Hao, Ping Wang & Frank J. Gonzalez. (2021) St. John’s Wort alleviates dextran sodium sulfate‐induced colitis through pregnane X receptor‐dependent NFκB antagonism. The FASEB Journal 35:11.
Crossref
Rooshi Nathwani, Benjamin Mullish, David Kockerling, Alexander Cole, Nowlan Selvapatt & Ameet Dhar. (2021) Review of Rifaximin: A Summary of the Current Evidence and Benefits Beyond Licensed Use. European Medical Journal, pages 94-100.
Crossref
Paolo Caraceni, Victor Vargas, Elsa Solà, Carlo Alessandria, Koos de Wit, Jonel Trebicka, Paolo Angeli, Rajeshwar P. Mookerjee, François Durand, Elisa Pose, Aleksander Krag, Jasmohan S. Bajaj, Ulrich Beuers & Pere Ginès. (2021) The Use of Rifaximin in Patients With Cirrhosis. Hepatology 74:3, pages 1660-1673.
Crossref
Gaia Anselmi, Lucilla Gagliardi, Gabriele Egidi, Sabrina Leone, Antonio GasbarriniGiacinto Abele Donato Miggiano & Leonarda Galiuto. (2020) Gut Microbiota and Cardiovascular Diseases. Cardiology in Review 29:4, pages 195-204.
Crossref
Veronica Lazar, Iulia Magdalena Vasilescu, Alina Maria Holban & Mariana Carmen Chifiriuc. 2020. Nutritional Signaling Pathway Activities in Obesity and Diabetes. Nutritional Signaling Pathway Activities in Obesity and Diabetes 191 209 .
Xi Chen, Han-Yu Li, Xiao-Min Hu, Yan Zhang & Shu-Yang Zhang. (2019) Current understanding of gut microbiota alterations and related therapeutic intervention strategies in heart failure. Chinese Medical Journal 132:15, pages 1843-1855.
Crossref
Daniela Weber, Andreas Hiergeist, Markus Weber, Katja Dettmer, Daniel Wolff, Joachim Hahn, Wolfgang Herr, André Gessner & Ernst Holler. (2019) Detrimental Effect of Broad-spectrum Antibiotics on Intestinal Microbiome Diversity in Patients After Allogeneic Stem Cell Transplantation: Lack of Commensal Sparing Antibiotics. Clinical Infectious Diseases 68:8, pages 1303-1310.
Crossref
Abraham S Meijnikman, Victor E Gerdes, Max Nieuwdorp & Hilde Herrema. (2018) Evaluating Causality of Gut Microbiota in Obesity and Diabetes in Humans. Endocrine Reviews 39:2, pages 133-153.
Crossref
Jeremy F.L. Cobbold, Stephen Atkinson, Julian R. Marchesi, Ann Smith, Sann N. Wai, Julie Stove, Fariba Shojaee-Moradie, Nicola Jackson, A. Margot Umpleby, Julie Fitzpatrick, E. Louise Thomas, Jimmy D. Bell, Elaine Holmes, Simon D. Taylor-Robinson, Robert D. Goldin, Michael S. Yee, Quentin M. Anstee & Mark R. Thursz. (2018) Rifaximin in non-alcoholic steatohepatitis: An open-label pilot study. Hepatology Research 48:1, pages 69-77.
Crossref
Stefan D. Holubar, Traci Hedrick, Ruchir Gupta, John Kellum, Mark Hamilton, Tong J. Gan, Monty G. Mythen, Andrew D. Shaw & Timothy E. Miller. (2017) American Society for Enhanced Recovery (ASER) and Perioperative Quality Initiative (POQI) joint consensus statement on prevention of postoperative infection within an enhanced recovery pathway for elective colorectal surgery. Perioperative Medicine 6:1.
Crossref
W.H. Wilson TangTakeshi KitaiStanley L. Hazen. (2017) Gut Microbiota in Cardiovascular Health and Disease. Circulation Research 120:7, pages 1183-1196.
Crossref
Miguel Saps & Adrian Miranda. 2017. Gastrointestinal Pharmacology. Gastrointestinal Pharmacology 147 176 .
Alessandro Menozzi, Manuel Dall’Aglio, Fausto Quintavalla, Luca Dallavalle, Valentina Meucci & Simone Bertini. (2016) Rifaximin is an effective alternative to metronidazole for the treatment of chronic enteropathy in dogs: a randomised trial. BMC Veterinary Research 12:1.
Crossref
D Weber, P J Oefner, K Dettmer, A Hiergeist, J Koestler, A Gessner, M Weber, F Stämmler, J Hahn, D Wolff, W Herr & E Holler. (2016) Rifaximin preserves intestinal microbiota balance in patients undergoing allogeneic stem cell transplantation. Bone Marrow Transplantation 51:8, pages 1087-1092.
Crossref
Alesa Courson, G. Morgan Jones & Jennifer D. Twilla. (2015) Treatment of Acute Hepatic Encephalopathy. Journal of Pharmacy Practice 29:3, pages 212-217.
Crossref
Takeshi Kitai, Jennifer Kirsop & W. H. Wilson Tang. (2016) Exploring the Microbiome in Heart Failure. Current Heart Failure Reports 13:2, pages 103-109.
Crossref
Joseph Buensalido, Carmen DeMarco & Stephen Lerner. 2015. Practical Handbook of Microbiology, Third Edition. Practical Handbook of Microbiology, Third Edition 153 182 .
Roberto Lorenzetti & Cosimo Prantera. (2013) Rationale for the use of rifaximin in inflammatory bowel diseases based on clinical trial results. Clinical Investigation 3:12, pages 1187-1193.
Crossref
Barjesh Chander Sharma, Praveen Sharma, Manish Kumar Lunia, Siddharth Srivastava, Rohit Goyal & S K Sarin. (2013) A Randomized, Double-Blind, Controlled Trial Comparing Rifaximin Plus Lactulose With Lactulose Alone in Treatment of Overt Hepatic Encephalopathy. American Journal of Gastroenterology 108:9, pages 1458-1463.
Crossref
Francesca D’Aversa, Annalisa Tortora, Gianluca Ianiro, Francesca Romana Ponziani, Brigida Eleonora Annicchiarico & Antonio Gasbarrini. (2013) Gut microbiota and metabolic syndrome. Internal and Emergency Medicine 8:S1, pages 11-15.
Crossref
Jie Cheng, Kristopher W. Krausz, Naoki Tanaka & Frank, J. Gonzalez. (2012) Chronic Exposure to Rifaximin Causes Hepatic Steatosis in Pregnane X Receptor-Humanized Mice. Toxicological Sciences 129:2, pages 456-468.
Crossref
Murat M. M. Harputluoglu, Ulvi Demirel, Mehmet Gul, Ismail Temel, Sule Gursoy, Engin Burak Selcuk, Murat Aladag, Yilmaz Bilgic, Ercan Gunduz & Yuksel Seckin. (2012) Effects of Rifaximin on Bacterial Translocation in Thioacetamide-Induced Liver Injury in Rats. Inflammation 35:4, pages 1512-1517.
Crossref
Jie Cheng, Yatrik M. Shah & Frank J. Gonzalez. (2012) Pregnane X receptor as a target for treatment of inflammatory bowel disorders. Trends in Pharmacological Sciences 33:6, pages 323-330.
Crossref
Richard G McGee, Anouk Bakens, Kerrie Wiley, Stephen M Riordan & Angela C Webster. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Sandeep Singh Sidhu & Omesh Goyal. (2011) Response to Zullo et al.. American Journal of Gastroenterology 106:11, pages 2041-2042.
Crossref
Kyoung Sup Hong & Joo Sung Kim. (2011) Rifaximin for the treatment of acute infectious diarrhea. Therapeutic Advances in Gastroenterology 4:4, pages 227-235.
Crossref
Emidio Scarpellini, Mariachiara Campanale, Diana Leone, Flaminia Purchiaroni, Giovanna Vitale, Ernesto Cristiano Lauritano & Antonio Gasbarrini. (2010) Gut microbiota and obesity. Internal and Emergency Medicine 5:S1, pages 53-56.
Crossref
Paul A. Aristoff, George A. Garcia, Paul D. Kirchhoff & H.D. Hollis Showalter. (2010) Rifamycins – Obstacles and opportunities. Tuberculosis 90:2, pages 94-118.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.